Caxton Associates LP Cyma Bay Therapeutics, Inc. Transaction History

Caxton Associates LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$5.88 - $9.59 $281,793 - $459,591	-47,924 Reduced 65.07%	25,725 $224,000
Q4 2022 Feb 14, 2023	BUY	$3.22 - $6.27 $45,804 - $89,190	14,225 Added 23.94%	73,649 $461,000
Q3 2022 Nov 14, 2022	SELL	$2.77 - $4.25 $126,805 - $194,556	-45,778 Reduced 43.51%	59,424 $208,000
Q2 2022 Aug 15, 2022	SELL	$1.72 - $3.39 $21,844 - $43,053	-12,700 Reduced 10.77%	105,202 $310,000
Q1 2022 May 16, 2022	BUY	$2.77 - $3.64 $326,588 - $429,163	117,902 New	117,902 $367,000

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Caxton Associates LP, based on Form 13F filings with the SEC.

Stay updated on Caxton Associates LP with notifications on news.